Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
Official title: Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining Its Regulation and Cellular Interactions
Funded at Dana-Farber Cancer Inst · NIH-11403920 · Data updated 2026-11-12
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 3, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $241,884 |
| NIH project number | 5K08CA300921-02 |
| Project ID | NIH-11403920 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with diffuse large B-cell lymphoma may contribute samples or participate in future related studies.
✕Less likely to help
This specific grant focuses on basic mechanisms and model systems; individual patients may not directly benefit during this project.
What this research studies
This project uses lab models of diffuse large B-cell lymphoma to uncover how HLA-E is regulated differently from other immune molecules. It will map the peptide targets presented by HLA-E in patient-derived samples and test how these peptides influence interactions with immune cells. The work involves genome-scale screens, in vitro experiments, and in vivo lymphoma models to understand the mechanism and its impact on immune recognition. The goal is to identify new angles to boost immune responses against this cancer.
Why it matters
Potential benefit: If successful, the research could reveal new targets to make the immune system better at recognizing and attacking DLBCL.
How similar studies have gone: Previous studies show HLA-E plays a role in immune interactions in cancer, but the exact regulation and peptide presentation in DLBCL are still being explored, making this a novel but plausible path.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Hahn, Cynthia — Dana-Farber Cancer Inst
- Study coordinator: Hahn, Cynthia
Related research
Other NIH-funded projects on the same topics.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
-
EBV-related lymphoma in people with immune deficiency: understanding what drives the disease
A doctor-scientist team will study a type of blood cancer linked to the Epstein-Barr virus in people with immune system problems to learn what makes it worse and how we can diagnose and treat it better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.